We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biochemical Marker to Predict the Recurrence of Atrial Fibrillation After Surgical Maze Procedure

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00542659
First Posted: October 11, 2007
Last Update Posted: July 25, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Samsung Medical Center
  Purpose

The role of plasma NT-proBNP, hsCRP, TIMP-1(Tissue inhibitors of MetalloProteinase-1),TGF-b, MMP-3(Matrix MetalloProteinase-3), and pro-MMP-1 in predicting the recurrence of AF after surgical Maze procedure.

The association of expression of CTGF, TGF-b, BNP, ANP, collagen-1, and collagen-3 in LA with the recurrence of AF after surgical Maze procedure.


Condition
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Plasma ANP and NT-pro-BNP, Atrial Anatomical Change May Determine the Outcome of Maze Operation

Resource links provided by NLM:


Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • AF recurrence [ Time Frame: year ]

Biospecimen Retention:   Samples Without DNA
plasma mRNA

Estimated Enrollment: 86
Study Start Date: February 2005
Study Completion Date: February 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The patients who have valvular heart disease with atrial fibrillation and are scheduled for operation
Criteria

Inclusion Criteria:

  • The patients who have valvular heart disease with atrial fibrillation and are scheduled for operation

Exclusion Criteria:

  • Coronary heart disease
  • Congestive heart failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00542659


Locations
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Young Keun On, MD Samsung Medical Center
  More Information

Responsible Party: Young Keun On, MD, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT00542659     History of Changes
Other Study ID Numbers: 2005-02-019
First Submitted: October 10, 2007
First Posted: October 11, 2007
Last Update Posted: July 25, 2011
Last Verified: July 2011

Keywords provided by Samsung Medical Center:
Atrial fibrillation
Maze procedure

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes